<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00176046</url>
  </required_header>
  <id_info>
    <org_study_id>WD 40</org_study_id>
    <nct_id>NCT00176046</nct_id>
  </id_info>
  <brief_title>Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study</brief_title>
  <official_title>Prospective Controlled Randomized Feasibility Study on a Treatment With Viscum Album in Patients With Breast Cancer to Identify Appropriate Surrogate Parameters for a Randomized Study of the Efficacy of Treatment With Mistletoe Extracts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Verein f체r Krebsforschung, Arlesheim, Swizzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weleda AG, D-73525 Schw채bisch Gm체nd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this feasibility study is to identify appropriate surrogate parameters for a
      randomized study to examine the efficacy of a complementary therapy with an extract of viscum
      album (Iscador P) in patients with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of three parts. Part 1 is a prospective non-randomized feasibility study
      in patients with breast cancer after primary surgery during chemotherapy or endocrine therapy
      comparing blood count, lymphocytes, quality of life and local and general side effects
      between the groups Part 2 is a prospective randomized feasibility study with a waiting list
      for three months comparing changes in quality of life, depression, diurnal cortisol profile
      and expression of zeta-chains in T- and NK-cells after three months of treatment or waiting
      in patients of two different strata (early breast cancer UICC I/II and metastatic breast
      cancer) Part 3 consists of two follow-up periods of 12 months respective. Patients may choose
      to continue, quit or restart mistletoe treatment upon their own decision, endpoints from part
      2 are evaluated every 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1999</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood count</measure>
    <time_frame>6-30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>lymphocytes</measure>
    <time_frame>6-30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>lymphocyte stimulation</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>quality of life</measure>
    <time_frame>6-30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>anxiety and depression</measure>
    <time_frame>6-30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>diurnal profile of cortisol</measure>
    <time_frame>6-30 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>expression of zeta-chains on T- and NK-cells</measure>
    <time_frame>6-30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>local reactions</measure>
    <time_frame>6-30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>documentation of concomitant medication</measure>
    <time_frame>6-30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>documentation of concomitant therapies</measure>
    <time_frame>6-30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>viscum album pini</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immediate start of treatment with Iscador P s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>waiting group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>identical treatment with Iscador P s.c. after waiting period of 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>viscum album pini</intervention_name>
    <description>s.c. injection of 0,001-20 mg 3 times per week</description>
    <arm_group_label>viscum album pini</arm_group_label>
    <other_name>Iscador P serie 0, 1, 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>viscum album pini</intervention_name>
    <description>s.c. injection 0,001-20 mg 3 times per week</description>
    <arm_group_label>waiting group</arm_group_label>
    <other_name>Iscador P Serie 0, 1, 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  breast cancer

          -  desire for additional therapy with mistletoe extracts

        Exclusion Criteria:

          -  contraindication for a therapy with mistletoe extracts(allergy, tuberculosis,
             hyperthyreosis, acute infectious disease, intracranial pressure in case of tumors or
             metastasis)

          -  current medication with glucocorticoids or other immunosuppressive therapies

          -  other concomitant complementary therapies

          -  prior therapy with mistletoe extracts &gt; 2 years or during the last 6 months

          -  karnofsky-Index &lt;60
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelia U. von Hagens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Complementary and Integrative Medicine Women's Hospital, University of Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Complementary and Integrative Medicine</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-W체rttemberg</state>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Cornelia von Hagens</investigator_full_name>
    <investigator_title>Head Complementary &amp; Integrative Medicine, Dep. 4.2</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>mistletoe</keyword>
  <keyword>complementary therapy</keyword>
  <keyword>quality of life</keyword>
  <keyword>immune function</keyword>
  <keyword>breast cancer (UICC stage I/II)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viscum album peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

